Novartis Corporation’s Zelnorm(R) to be Made Available to US Patients Under Restricted Access Program

EAST HANOVER, N.J., July 27 /PRNewswire/ -- In cooperation with the US Food and Drug Administration (FDA), Novartis has established a restricted access program for Zelnorm® (tegaserod maleate) so that patients in need of this medicine can be considered for treatment.

MORE ON THIS TOPIC